IL-6R–related diseases like mycosis fungoides, castleman's disease, as well as inflammatory disorders such as rheumatoid arthritis and other cutaneous diseases are currently of interest for PDT and their treatment might be improved by further development of aptamer conjugates in the future.41,42,43. This evidence concerns the gene IL6R and rheumatoid arthritis.